MedTrace Logo

Identifying Biomarkers for Endothelial Dysfunction in Women With Preeclampsia

NCT07084727 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-24

No results posted yet for this study

Summary

Every pregnancy has a major impact on a woman's heart and blood vessels due to changes required by the body to maintain proper blood flow between mother and foetus. When the placenta does not work properly, preeclampsia can occur. An important first symptom is high blood pressure. Women who have experienced preeclampsia are at higher risk of developing blood pressure and heart problems later on. Therefore, it is very important to detect changes in the blood vessel system so that they can be treated promptly and correctly. We aim to do this by using a new, non-invasive eye test that examines the blood vessels of the retina.

Conditions

Interventions

OTHER

Arterial stiffness

Non-invasive test. A blood pressure cuff and tonometer (a type of pen placed on the neck) are used to measure the speed at which a pressure wave propagates from one place to another. Every time the heart contracts, a pressure wave is generated that propagates from the heart to the blood vessels at a certain speed. The stiffer the blood vessels, the faster the wave propagates.

OTHER

Flow-meditad dilatation

This study measures the capacity with which blood vessels expand when we briefly cut off blood flow. The endothelium, the inner layer of blood vessels, regulates this expansion. By ultrasound, we measure the difference in diameter of the elbow artery. To cut off the blood flow, we clamp the forearm with a blood pressure cuff for 5 minutes. When the blood pressure cuff is released, it triggers increased blood flow in the arm, causing the blood vessels to expand. We record this expansion using the above techniques.

OTHER

Dynamic retinal vessel analyzer

Eye imaging measures the capacity with which your blood vessels in the retina can expand in response to a flicker light stimulation.

Sponsors & Collaborators

  • University Hospital, Antwerp

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-11-15
Completion
2025-12-15

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07084727 on ClinicalTrials.gov